NBM-BMX softgel capsules(NBM-BMX softgel capsules) - 药物靶点：HDAC8_在研适应症：肿瘤，胶质母细胞瘤，阿尔茨海默症_专利_临床

概要

基本信息

药物类型

小分子化药

别名

NBM BMX softgel capsules、NBM-BMX、NBM BMX

+ [1]

靶点

HDAC8

作用机制

HDAC8抑制剂(组蛋白去乙酰化酶-8抑制剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

非在研机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)临床2期

特殊审评-

登录后查看时间轴

结构

分子式C23H27NO5

InChIKeySOWOYQPLOHLYEY-NTEUORMPSA-N

CAS号1246952-34-0

关联

4

项与 NBM-BMX softgel capsules 相关的临床试验

NCT06012695 / Recruiting临床1/2期

A Phase Ib/II, Open-label Study of NBM-BMX as Monotherapy or in Combination With Radiotherapy and Temozolomide in Subjects With Solid Tumors or Newly Diagnosed Glioblastoma

NBM-BMX is an orally available new chemical entity to inhibit histone deacetylases 8 (HDAC8) activity specifically, being developed as a potential anti-cancer therapeutic by NatureWise. This study aims to evaluate the safety, pharmacokinetics, and preliminary efficacy of NBM-BMX as monotherapy in subjects with advanced solid tumors or combination with the standard of care treatment in subjects with newly diagnosed glioblastoma.

开始日期2023-08-11

申办/合作机构-

IRCT20180610040037N5 / Recruiting临床3期IIT

Examining the Effectiveness and Side Effects of Softgel-Encapsulated IMOD in Individuals Living with HIV

开始日期2023-07-23

申办/合作机构

Tehran University of Medical Sciences

NCT03808870 / Completed临床1期

A Phase 1, Open-label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Efficacy of NBM-BMX in Asian Subjects With Advanced Solid Tumors

NBM-BMX is an orally available new chemical entity to inhibit HDAC8 activity specifically, being developed as a potential anti-cancer therapeutic by NatureWise. The objectives of this study are to evaluate the safety, pharmacokinetics, and preliminary efficacy of NBM-BMX as monotherapy in subjects with advanced solid tumors (Arm A) or in combination with the standard of care treatment (i.e., concomitant RT/TMZ followed by adjuvant TMZ) in subjects with newly diagnosed glioblastoma (Arm B).

开始日期2018-12-28

申办/合作机构

彦臣生技药品股份有限公司

100 项与 NBM-BMX softgel capsules 相关的临床结果

登录后查看更多信息

100 项与 NBM-BMX softgel capsules 相关的转化医学

登录后查看更多信息

100 项与 NBM-BMX softgel capsules 相关的专利（医药）

登录后查看更多信息

104

项与 NBM-BMX softgel capsules 相关的文献（医药）

2024-06-06·International journal of phytoremediation

Effective removal of malachite green oxalate from aqueous solution using Newbouldia laevis husk/MWCNTs nanocomposite: equilibrium, kinetics, and thermodynamics

Article

作者: Taziwa, Raymond ; Amaku, Friday James

The discharge of colored effluent into water bodies is a big concern; hence, the current work was designed to fabricate a superior nanocomposite (NBM) using the Newbouldia laevis husk (NB) and functionalized multiwalled carbon nanotubes (f-MWCNTs) for the adsorption of malachite green oxalate (MGO). Brunauer-Emmett-Teller (BET) surface analysis was used to assess the specific surface area of NB (0.7699 m² g^-1) and NBM (94.006 m² g^-1). Fourier transform infrared spectroscopy (FTIR) was employed to determine the chemical moieties on the surface of the adsorbent. Field emission scanning electron microscopy (FESEM) and thermogravimetric analysis (TGA) were used to analyze the surface morphology and the thermal behavior of the adsorbents. Essential factors of the adsorption process were investigated, and it was revealed that pH 6.0, adsorbent dose of 0.05 g, contact time 80 min, concentration of 100 mg dm^-3 and maximum adsorption capacity of 35.78 mg g^-1 (NB) and 69.97 mg g^-1 (NBM) were the optimal parameters. The NB and NBM adsorption processes followed a pseudo-first-order kinetic model. The exothermic and endothermic adsorptive processes were noticed to be the best descriptions of MGO elimination by NB and NBM, respectively. The uptake of MGO by NB and NBM was best described by models of Freundlich and Langmuir isotherms. Besides, NBM demonstrated uptake efficiency that is >80% after the fourth adsorption/desorption cycle. As a result, NBM has a wide range of possible uses in environmental remediation.

2024-04-01·World neurosurgery

Deep Brain Stimulation as an Emerging Therapy for Cognitive Decline in Alzheimer Disease: Systematic Review of Evidence and Current Targets

Review

作者: Brown, Nolan J ; Wong, Joey ; Dutta, Rajeev R ; Lopez, Alexander M ; Picton, Bryce ; Oh, Michael Y ; Solomon, Sean S ; Paff, Michelle R ; Hsu, Frank P ; Andalib, Saman

OBJECTIVE:

With no cure for Alzheimer disease (AD), current efforts involve therapeutics that prevent further cognitive impairment. Deep brain stimulation (DBS) has been studied for its potential to mitigate AD symptoms. This systematic review investigates the efficacy of current and previous targets for their ability to slow cognitive decline in treating AD.

METHODS:

A systematic review of the literature was performed through a search of the PubMed, Scopus, and Web of Science databases. Human studies between 1994 and 2023 were included. Sample size, cognitive outcomes, and complications were recorded for each study.

RESULTS:

Fourteen human studies were included: 7 studies with 6 distinct cohorts (n = 56) targeted the fornix, 6 studies with 3 distinct cohorts (n = 17) targeted the nucleus basalis of Meynert (NBM), and 1 study (n = 3) investigated DBS of the ventral striatum (VS). The Alzheimer's Disease Assessment Scale-Cognitive Subscale, Mini-Mental State Examination, and Clinical Dementia Rating Scale Sum of Boxes were used as the primary outcomes. In 5 of 6 cohorts where DBS targeted the fornix, cognitive decline was slowed based on the Alzheimer's Disease Assessment Scale-Cognitive Subscale or Mini-Mental State Examination scores. In 2 of 3 NBM cohorts, a similar reduction was reported. When DBS targeted the VS, the patients' Clinical Dementia Rating Scale Sum of Boxes scores indicated a slowed decline.

CONCLUSIONS:

This review summarizes current evidence and addresses variability in study designs regarding the therapeutic benefit of DBS of the fornix, NBM, and VS. Because of varying study parameters, varying outcome measures, varying study durations, and limited cohort sizes, definitive conclusions regarding the utility of DBS for AD cannot be made. Further investigation is needed to determine the safety and efficacy of DBS for AD.

2023-08-01·Journal of environmental management

Revealing the mechanism of novel nitrogen-doped biochar supported magnetite (NBM) enhancing anaerobic digestion of waste-activated sludge by sludge characteristics

Article

作者: Zou, Xiang ; He, Junguo ; Pan, Xinlei ; Zhang, Pengfei ; Zhong, Yijie ; Zhang, Jie ; Cai, Qiupeng ; Duan, Shengye

Anaerobic digestion (AD) is a promising technology in waste treatment and energy recovery. However, it suffers from long retention time and low biogas yield. In this study, novel nitrogen-doped biochar supported magnetite (NBM) was synthesized and applied to enhance the AD of waste-activated sludge. Results showed that NBM increased cumulative methane production and SCOD removal efficiency by up to 1.75 times and 15% respectively at 5 g/L compared with the blank. NBM enhanced both hydrolysis and methanogenesis process during AD and the activities of α-glucosidase, protease, coenzyme F₄₂₀ and electron transport system were increased by 19%, 163%, 104% and 160% respectively at 5 g/L NBM compared with the blank. NBM also facilitated the secretion of conductive protein in extracellular polymeric substances as well as the formation of conductive pili, leading to 3.18-7.59 times higher sludge electrical conductivity. Microbial community analysis revealed that bacteria Clostridia and archaea Methanosarcina and Methanosaeta were enriched by the addition of NBM, and direct interspecies electron transfer might be promoted between them. This study provides a practical reference for future material synthesis and its application.

100 项与 NBM-BMX softgel capsules 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
胶质母细胞瘤	临床2期	中国台湾	-	2023-08-11
肿瘤	临床2期	中国	彦臣生技药品股份有限公司	2022-08-24
阿尔茨海默症	临床1期	中国	彦臣生技药品股份有限公司	2022-08-24
晚期癌症	临床1期	美国	彦臣生技药品股份有限公司	2018-10-16
晚期恶性实体瘤	临床1期	美国	彦臣生技药品股份有限公司	2018-10-16